Verona Pharma (VRNA)
(Delayed Data from NSDQ)
$37.59 USD
-0.80 (-2.08%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $37.59 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
VRNA 37.59 -0.80(-2.08%)
Will VRNA be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for VRNA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VRNA
Recent Price Trend in Verona Pharma (VRNA) is Your Friend, Here's Why
Zacks Industry Outlook Highlights Exelixis, Blueprint Medicines, CRISPR, Amicus and Verona Pharma
VRNA: What are Zacks experts saying now?
Zacks Private Portfolio Services
5 Biotech Stocks Likely to Outperform as Industry Prospects Look Bright
Wall Street Analysts Think Verona Pharma (VRNA) Could Surge 25.25%: Read This Before Placing a Bet
Verona Pharma (VRNA) Is a Great Choice for 'Trend' Investors, Here's Why
Other News for VRNA
Verona Pharma management to meet with BTIG
Verona Pharma management to meet with BTIG
Biotech Alert: Searches spiking for these stocks today
Biotech Alert: Searches spiking for these stocks today
Verona Pharma PLC CFO Mark Hahn Sells 129,672 Shares